Well, REGAIN is a trial of galcanezumab in chronic migraine patients. There was a placebo-controlled trial for 3 months, and after 3 months, patients rolled over into active drug. Basically every patient in the trial had active galcanezumab 120 milligrams a month. The study could show that galcanezumab is efficacious over this entire open treatment period, so it reduces monthly migraine days significantly, it improves quality of life, it reduces acute medication intake, and it helps to improve the entire disease...
Well, REGAIN is a trial of galcanezumab in chronic migraine patients. There was a placebo-controlled trial for 3 months, and after 3 months, patients rolled over into active drug. Basically every patient in the trial had active galcanezumab 120 milligrams a month. The study could show that galcanezumab is efficacious over this entire open treatment period, so it reduces monthly migraine days significantly, it improves quality of life, it reduces acute medication intake, and it helps to improve the entire disease.
I think next what’s coming up is head-to-head comparator trials of monoclonal antibodies versus small-molecule CGRP receptor antagonists. We have head-to-head trials of oral migraine preventatives, topiramate versus monoclonal antibodies, erenumab, for example, and of course, we have the small molecules coming to the market for acute migraine treatment and for migraine prevention.